Autologous hematopoietic stem cell transplantation in the treatment of patients with poor-prognosis non-Hodgkin iymphoma

( views:, downloads: )
Author:
CHEN Bo(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
MA Jun(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
WANG Zhi-guo(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
XIAO Liang(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
ZHANG Hao(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
FAN Yan-ling(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
XIA Guo-qiong(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
QIU Lin(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
ZHAN Zhao-min(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
ZHANG Bo-long(Department of Hematology, The Harbin Institute of Hematology & Oncology, Harbin 150010, China)
Journal Title:
JOURNAL OF LEUKEMIA & LYMPHOMA
Issue:
Volume 18, Issue 10, 2009
DOI:
10.3760/cma.j.issn.1009-9921.2009.10.009
Key Word:
Lymphoma, non-Hodgkin; Peripheral blood stem cell transplantation; Transplantation, autologous; Prognosis

Abstract: Objective To observe the therapeutic effectiveness and safety of autologous peripheral blood stem cell transplantation (APBSCT) for poor-risk non-Hodgkin lymphoma (NHL). Methods Ten patients with poor-prognosis NHL were enrolled from October 2003 to October 2008 in our institute. Ten patients were treated by APBSCT with CY+TBI conditioning regimen (Two patients of them were treated by Double-APBSCT with MEC conditioning regimen). Results Hematopoietic reconstitution was observed in all patients.The time of neutrophil count ≥0.5×109L and platelet≥20×109/L were at day 10 (range: 7-14) and day 16 (range: 10-37), respectively. All patients achieved complete remission (CR) after transplantation. Severe toxicity and transplant related mortality were not observed. After a median follow-up of 24 (10-84) months,seven cases were in event-free survival and three cases relapsed. One of three relapsed patients died from progression of disease, the other was still alive after treatment. Conclusion APBSCT in the treatment of patients with poor-prognosis NHL is a safe, convenient and efficient treatment.

  • [1]张之南,杨天楹,郝玉书.血液病学.北京:人民卫生出版社,2005:1306-1333.
  • [2]崔洪新,白波,陈维刚,等.自体造血干细胞移植治疗恶性淋巴瘤的研究进展.实用医药杂志,2004,21:168-169.
  • [3]董陆佳,叶根耀.现代造血干细胞移植治疗学.北京:人民军医出社,2001:418-425.
  • [4]Gutierrez-Dekgado F,Maloney DG,Press OW,et al.Autologous stem cell transplantation for non-Hodgkin's lymphoma:comparison of radiation-based and chemotherapy-only preparative regimens.Bone Marrow Transplant,2001,28:455.
  • [5]Gianni AM,Bregni M,Siena S,et al.High-dose chemotherapy and antologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.N Engl J Med,1997,336:1290-1297.
  • [6]陈昀,沈志祥.2008年第3版NCCN-NHL指南更新解读--滤泡性淋巴瘤.白血病·淋巴瘤,2009,18:494-495.
  • [7]Smith T J,Hillner BE,Schmitz N,et al.Economic analysis of a randomized clinical trial to compare filgrasstim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma.J Clin Oncol,1997,15:5-10.
  • [8]达万明,裴雪涛.外周血干细胞移植.北京:人民卫生出版社,2000:45-90.
  • [9]Schmite N,Ddrger P,Zander AR,et al.Results of a randomised,controlled,multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's lymphoma undergoing autologous bone marrow transplantation.Bone Marrow Transplant,1995,15:261.
  • [10]Kewalramani T,Zelenetz AD,Hedrick EE,et al.High-does chemoradiotherapy and autologous stem cell transplantation for paitients with primary refractory aggressive non-Hodgkin's lymphoma:an intention-to-treat analysis.Blood,2000,96:2399-2404.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn